GLPwatch
Papers (12034)
Page 80 of 201, ranked by citation count.
- Therapeutic Potential of Liraglutide for Diabetes-Periodontitis Comorbidity: Killing Two Birds with One Stone.
- Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).
- Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
- Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).
- Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.
- In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.
- Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca<sup>2+</sup> channel.
- Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
- Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
- Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
- The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.
- A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
- The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.
- Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
- Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
- Semaglutide: a new drug for the treatment of obesity.
- Exendin-4 enhances radiation response of prostate cancer.
- The impact of approved anti-obesity medications on osteoarthritis.
- LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION.
- GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
- Semaglutide, lipid-lowering drugs, and NAFLD.
- Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO<sup>2</sup> S-RWD).
- Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.
- Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.
- Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
- Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
- <i>Lactobacillus reuteri</i> JCM 1112 ameliorates chronic acrylamide-induced glucose metabolism disorder <i>via</i> the bile acid-TGR5-GLP-1 axis and modulates intestinal oxidative stress in mice.
- Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.
- Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.
- Pharmacological Treatment of Obesity in Older Adults.
- Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
- Adjunct therapies in treatment of type 1 diabetes.
- Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.
- Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?
- How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense?
- Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.
- Shielding effect of a PEG molecule of a mono-PEGylated peptide varies with PEG chain length.
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
- Triple Agonism Based Therapies for Obesity.
- Oral delivery of liraglutide-loaded Poly-N-(2-hydroxypropyl) methacrylamide/chitosan nanoparticles: Preparation, characterization, and pharmacokinetics.
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
- Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
- GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.
- Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.
- Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes.
- Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.
- Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.
- GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.
- Semaglutide for weight loss: unanswered questions.
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
- Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.
- Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- Obesity drugs aren't always forever. What happens when you quit?
- Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.
- Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
- α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
- Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
- Long-term feeding on powdered food causes hyperglycemia and signs of systemic illness in mice.